secwatch.observer — SEC 8-K summary
======================================

Issuer:     Emergent BioSolutions Inc. (EBS)
CIK:        0001367644
Form:       8-K
Filed at:   2023-02-27T23:59:59+00:00
Accession:  0001367644-23-000024
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Emergent BioSolutions Q4 2022 net loss $88M, revenue $331M (-54% YoY); FY2023 guidance issued
--------------------------------------------------------------------------------

- Q4 2022 total revenues $330.7M vs $723.2M in Q4 2021; net loss $88.0M vs net income $189.3M.
- Full year 2022 revenues $1,120.9M (-37% YoY); net loss $223.8M vs net income $230.9M.
- FY2023 guidance: revenues $1.1-1.2B, adjusted EBITDA $75-125M, adjusted gross margin 41-44%.
- Agreed to sell travel health business to Bavarian Nordic for up to $380M; FDA priority review for NARCAN OTC.
- Eliminated 132 positions with annualized savings >$60M; DoD RSDL contract valued up to $379.6M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1367644/000136764423000024/0001367644-23-000024-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1367644/000136764423000024/ebs-20230227.htm
  HTML page:      https://secwatch.observer/filing/0001367644-23-000024

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer